Related Experiment Video
Updated: Aug 8, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease
1Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand.
Insights
Statins significantly lower cardiac event risk by reducing LDL cholesterol. However, optimal LDL levels and the mechanisms of action for statins versus fibrates require further clinical consideration for cardiovascular disease management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- HMG CoA reductase inhibitors (statins) have demonstrated a 30-35% reduction in cardiac events with 25-35% LDL cholesterol decrease.
- Emerging data suggest minimal additional benefit in reducing cardiac events when LDL cholesterol is lowered below 3.2 mmol/L.
- Debate exists regarding whether observed cardiovascular event reductions are solely due to LDL lowering or involve other pleiotropic effects of lipid-modifying agents.
Purpose of the Study:
- To evaluate the efficacy of lipid-modifying agents in cardiovascular disease prevention.
- To compare the mechanisms of action between statins and fibrates.
- To guide clinical decisions regarding the choice of lipid-lowering therapy based on lipoprotein phenotype.
Main Methods:
- Analysis of data from recent clinical trials (4S, CARE, WOSCOPS) involving HMG CoA reductase inhibitors.
- Review of preliminary data on achieved LDL cholesterol levels and their impact on cardiac events.
- Comparative assessment of the pharmacological actions of statins and fibrates on lipid metabolism and cardiovascular pathways.
Main Results:
- Statins effectively reduce cardiac event risk, with significant benefits observed for LDL cholesterol reduction.
- Preliminary findings indicate a plateau effect, with no substantial additional reduction in cardiac events when LDL cholesterol is reduced below 3.2 mmol/L.
- Fibrates offer a distinct therapeutic approach by targeting triglyceride-rich lipoprotein precursors and improving LDL and HDL composition, effects often overshadowed by statin trial results.
Conclusions:
- While statins are proven effective, the precise mechanisms contributing to cardiovascular event reduction warrant further investigation.
- The role of fibrates in managing cardiovascular disease, distinct from statins, requires renewed clinical consideration.
- Clinicians must individualize treatment strategies, considering the patient's lipoprotein phenotype to select optimal therapy, potentially including statins alone, fibrates alone, or combination therapy.
Abstract:
1. Recent studies (4S, CARE, WOSCOPS) with the HMG CoA reductase inhibitors have shown that reductions of total cholesterol and LDL cholesterol reduce the risk for a new fatal or non-fatal cardiac event by approximately 30-35%, providing LDL is decreased by 25-35%. 2. Preliminary data also suggest that achieved LDL levels around 3.2 mmol/L results in no greater reduction in new events than when LDL is lowered even further. 3. There is considerable debate, nonetheless, as to whether these reduction in cardiovascular events are entirely a consequence of LDL reduction or whether the lipid-modifying agents have effects on lipoprotein structure, endothelial cell function, clotting and haemorrheological pathways. 4. The study results achieved with statins have obscured the role of fibrates as useful agents for reducing cardiovascular disease. Fibrates have a different mode of action to stains by reducing triglyceride-rich lipoprotein precursors and favourably altering LDL and HDL composition. 5. The practising clinician needs to consider the lipoprotein phenotype and to choose whether the ideal treatment is stain alone, fibrate alone or perhaps a combination.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management